Relmada Therapeutics Inc expected to post a loss of 64 cents a share - Earnings Preview

Relmada Therapeutics

04/11/2024 22:20

* Relmada Therapeutics Inc  RLMD.OQ   RLMD.O  is expected
to show
no change in quarterly revenue when it reports  results on
November 6 (estimated) for the period ending September 30 2024
    * 
    * ​LSEG's mean analyst estimate for Relmada Therapeutics Inc
is
for a loss of 64 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 3 "strong buy" or "buy," no
"hold" and 1 "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Relmada
Therapeutics Inc is $11.50​, above​ its last closing price
of $3.49. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  LSEG IBES  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  ESTIMATE             MET,    SE %
               E®                               MISSED  
 Jun. 30 2024  -0.81       -0.83      -0.59     Beat    28.6
 Mar. 31 2024  -0.84       -0.85      -0.72     Beat    15.2
 Dec. 31 2023              -0.83      -0.84     Missed  -1.2​
 Jan. 1 0001   -0.91       -0.91      -0.73     Beat    20
 ​​Jun.        -0.90       -0.90      -0.84     Beat    6.3
 30 2023                                                
 Mar. 31 2023  -0.91       -0.89      -0.87     Beat    2.2​
 Dec. 31 2022              -1.33      -1.41     Missed  -6.2
 Jan. 1 0001   -1.44       -1.45      -1.31     Beat    9.6
 This summary was machine generated November 4 at 22:20 GMT.  All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)